Tartrate-resistant acid phosphatase as a marker of bone metastases in patients with breast cancer and prostate cancer

Lyubimova, N. V.; Pashkov, M. V.; Tyulyandin, S. A.; Goldberg, V. Е.; Кушлинский, Н Е

doi:10.1007/bf02694481

Cited by 27 publications

(13 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Currently, a kinetic assay to measure specifically type-5b TRAP, a desialylated isoenzyme present only in osteoclasts and alveolar macrophages, has been described 53,54 . Increased type-5b TRAP levels have been described in conditions associated with increased bone resorption such as end-stage renal failure, hemodialysis bone disease, and metastatic bone disease [55][56][57][58] .…”

Section: Bone Resorption Markersmentioning

confidence: 99%

The Assessment of Fracture Risk

Unnanuntana

Gladnick

Donnelly

et al. 2010

The Journal of Bone and Joint Surgery-American Volume

315

207

View full text Add to dashboard Cite

Bone mineral density is considered to be the standard measure for the diagnosis of osteoporosis and the assessment of fracture risk. The majority of fragility fractures occur in patients with bone mineral density in the osteopenic range.ä The Fracture Risk Assessment Tool (FRAX) can be used as an assessment modality for the prediction of fractures on the basis of clinical risk factors, with or without the use of femoral neck bone mineral density. Treatment of osteoporosis should be considered for patients with low bone mineral density (a T-score of between 21.0 and 22.5) as well as a ten-year risk of hip fracture of ‡3% or a ten-year risk of a major osteoporosis-related fracture of ‡20% as assessed with the FRAX.ä Biochemical bone markers are useful for monitoring the efficacy of antiresorptive or anabolic therapy and may aid in identifying patients who have a high risk of fracture.ä An approach combining the assessment of bone mineral density, clinical risk factors for fracture with use of the FRAX, and bone turnover markers will improve the prediction of fracture risk and enhance the evaluation of patients with osteoporosis.

show abstract

Section: Bone Resorption Markersmentioning

confidence: 99%

The Assessment of Fracture Risk

Unnanuntana

Gladnick

Donnelly

et al. 2010

The Journal of Bone and Joint Surgery-American Volume

315

207

View full text Add to dashboard Cite

show abstract

“…The role of osteoclasts in disease is well documented for several bone disorders, such as osteoporosis, Paget's disease, and rheumatoid arthritis (7). Over the last decade, the role of the osteoclast in metastatic disease associated with multiple myeloma (8,9), prostate cancer (10,11), or breast cancer (12)(13)(14)(15) has received considerable attention. Numerous animal and clinical studies strongly suggest the involvement of osteoclasts in enhancing the occurrence and progression of metastases in the bone microenvironment by mediating the release of factors such as interleukin (IL)-1 and transforming growth factor-β that stimulate the growth of metastatic cancer cells (10,(16)(17)(18)(19)(20).…”

Section: Introductionmentioning

confidence: 99%

Loss of Osteoclasts Contributes to Development of Osteosarcoma Pulmonary Metastases

et al. 2010

View full text Add to dashboard Cite

We conducted a transcriptomic screen of osteosarcoma (OS) biopsies and found that expression of osteoclast-specific tartrate-resistant acid phosphatase 5 (ACP5/TRAP) is significantly downregulated in OS compared with nonmalignant bone (P < 0.0001). Moreover, lesions from OS patients with pulmonary metastases had 2-fold less ACP5/TRAP expression (P < 0.018) than lesions from patients without metastases. In addition, we found a direct correlation (P = 0.0166) between ACP5/TRAP expression and time to metastasis. Therefore, we examined whether metastasis-competent (MC) OS cells could induce loss of ACP5 + osteoclasts and contribute to metastasis. We found that MC OS cell lines can inhibit osteoclastogenesis in vitro and in vivo. In addition, osteoclasts can inhibit the migration of MC OS cells in vitro. Finally, ablation of osteoclasts with zoledronic acid increases the number of metastatic lung lesions in an orthotopic OS model, whereas fulvestrant treatment increases osteoclast numbers and reduces metastatic lesions. These data indicate that the metastatic potential of OS is determined early in tumor development and that loss of osteoclasts in the primary lesion enhances OS metastasis.

show abstract

“…Lyubimova et al report that TRACP 5b detect bone metastases with a sensitivity of 82% and a specificity of 87% in patients with mammary carcinoma and with a sensitivity of 71% and a specificity of 83% in patients with prostate carcinoma [13]. Likewise, a study by Korpela et al illustrates in patients with mammary carcinoma significantly increased values of TRACP 5b in case of bone metastases.…”

Section: Bone Trap Assaymentioning

confidence: 94%

“…Jung et al [10] and Kamiya et al [18] find significantly elevated concentrations of different bone formation and resorption markers in case of bone metastases. The results of Halleen et al [11], Lyubimova et al [13], Chao et al [14],and Yao et al [15] show promising findings regarding the bone resorption marker TRACP 5b in the question of bone metastases.…”

Section: Bone Trap Assaymentioning

confidence: 95%

“…Previous studies by Halleen et al [11], Lyubimova et al [13], Chao et al [14], and Yao et al [15] demonstrated that bone metastases of different tumors influence bone metabolism and induce significantly elevated serum levels of TRACP 5b. With regard to bone metastases of RCC, a study by Jung et al [16] appears to contradict the above reports.…”

Section: Introductionmentioning

confidence: 96%

See 1 more Smart Citation

Untitled

2014

Integr Cancer Sci Therap

View full text Add to dashboard Cite

The objective of this study was to assess the diagnostic value of the bone resorption marker tartrate-resistant acid phosphatase isoform5b (TRACP 5b) in detecting bone metastases in patients with renal cell carcinoma (RCC). Serum samples of 64 patients with histologically proven RCC were analyzed. Using bone scintigraphy, these patients were divided into 2 groups: 30 patients with RCC without bone metastases and 34 patients with RCC with bone metastases. TRACP 5b concentrations were analyzed in the serum using the Bone TRAP Assay. TRACP 5b concentrations were significantly elevated (p=0.014) in patients with bone metastases (median: 31.9 U/L) compared with patients without bone metastases (median: 8.7 U/L). Elevated TRACP 5b concentrations detected bone metastases with sensitivity of 76.5% and specificity of 36.7%. TRACP 5b appears to be an effective biomarker of bone metastases in patients with RCC.

show abstract

Tartrate-resistant acid phosphatase as a marker of bone metastases in patients with breast cancer and prostate cancer

Cited by 27 publications

References 6 publications

The Assessment of Fracture Risk

The Assessment of Fracture Risk

Loss of Osteoclasts Contributes to Development of Osteosarcoma Pulmonary Metastases

Untitled

Contact Info

Product

Resources

About